Atomoxetine and Cerebrovascular Outcomes in Adults
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to estimate the association between atomoxetine and cerebrovascular accident (CVA) and transient ischemic attack (TIA) in adults. METHODS: This cohort study conducted within a health insurance database included 21,606 atomoxetine initiators matched to 21,606 stimulant attention-deficit/hyperactivity disorder (ADHD) medication initiators on the basis of propensity scores and a sample from the source population (N = 42,993). Outcomes were confirmed through a medical record review or a National Death Index search. Poisson regression was used to estimate the rate ratio and 95% confidence interval (CI) of CVA or TIA according to the treatment. Cox regression was used to estimate the hazards ratio (HR) and 95% CI for comparisons across cohorts. RESULTS: Forty-four CVAs and 21 TIAs occurred during a mean follow-up of 1.5 years. The rate ratio of the current atomoxetine compared with the current stimulant ADHD medication was 1.38 for CVA (95% CI, 0.42-4.54) and 0.31 for TIA (95% CI, 0.04-2.63). Results for atomoxetine compared with the stimulant ADHD medication according to initial cohort assignment were consistent, with no increased risk for CVA or TIA. An increased risk of TIA was observed between initiation of an ADHD medication compared with the general population (HR, 3.44; 95% CI, 1.13-10.60); however, a similar pattern was not observed for CVA (HR, 0.71; 95% CI, 0.34-1.47). CONCLUSIONS: These results do not support an increased risk of CV events with atomoxetine compared with the stimulant ADHD medication. Users of ADHD medications may be at an increased risk of TIA compared with the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 1×
“We used the first dispensing after at least 6 months without dispensing as an operational definition of a new user or initiator of the medication.(12) Members were required to have commercial health insurance coverage, complete medical and pharmacy benefits, and 6 months of continuous enrollment before the first dispe…”
MethodBiederman, J., Mick, E., Surman, C., Doyle, R., Hammerness, P., Harpold, T., Dunkel, S., Dougherty, M., Aleardi, M., & Spencer, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.011 · Cited by 267
Comorbidities and Costs of Adult Patients Diagnosed with Attention-Deficit Hyperactivity Disorder
Secnik, K., Swensen, A., & Lage, M. J. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523010-00008 · Cited by 247
Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults
Wernicke, J. F., Faries, D., Girod, D., Brown, J. W., Gao, H., Kelsey, D., Quintana, H., Lipetz, R., Michelson, D., & Heiligenstein, J. (2003) · Drug Safety · doi:10.2165/00002018-200326100-00006 · Cited by 191
Cited by
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Validity of diagnostic codes for acute stroke in administrative databases: a systematic review.
McCormick, N., Bhole, V., Lacaille, D., & Avina-Zubieta, J. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135834 · Cited by 414
ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
Habel, L. A., Cooper, W. O., Sox, C. M., Chan, K. A., Fireman, B. H., Arbogast, P. G., Cheetham, T. C., Quinn, V. P., Dublin, S., Boudreau, D. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1830 · Cited by 297
“In one study, users of ADHD medications had a more than 3-fold higher rate of transient ischemic attacks but a 30% lower rate of cerebrovascular accidents, although the latter was not statistically significant.(17) In contrast, no increase in SCDs among children, adolescents, or young adults was observed in a second c…”
BackgroundResultAndrade, S. E., Harrold, L. R., Tjia, J., Cutrona, S. L., Saczynski, J. S., Dodd, K. S., Goldberg, R. J., & Gurwitz, J. H. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2312 · Cited by 268
Dalsgaard, S., Kvist, A. P., Leckman, J. F., Nielsen, H. S., & Simonsen, M. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0020 · Cited by 121
Metadata
- Authors
- Holick, C. N., Turnbull, B. R., Jones, M. E., Chaudhry, S., Bangs, M. E., & Seeger, J. D.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2009-10
- Volume
- 29
- Issue
- 5
- Pages
- 453-460
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2070421435
- Cited by
- 42
- References
- 4
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atomoxetine and Cerebrovascular Outcomes in Adults. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181b2b828
- The paper
- Holick, C. N., Turnbull, B. R., Jones, M. E., Chaudhry, S., Bangs, M. E., & Seeger, J. D. (2009). Atomoxetine and Cerebrovascular Outcomes in Adults. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181b2b828
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.